For PN-associated metabolic bone disease risk in IBD patients requiring long-term PN, which of the following is implicated?

For PN-associated metabolic bone disease risk in IBD patients requiring long-term PN, which of the following is implicated?

• A. Hypercalcemia and magnesium excess
• B. Hypophosphatemia and zinc deficiency
• C. Hypercalciuria and aluminum toxicity
• D. Vitamin D toxicity

Answer: (C)

The risk for PN-associated metabolic bone disease in patients on long-term parenteral nutrition centers on imbalances from the IV nutrition itself, especially exposure to aluminum and how calcium handling is managed. Aluminum toxicity from PN solutions is a well-recognized cause of impaired bone mineralization (osteomalacia) and contributes to overall bone disease in these patients. At the same time, calcium metabolism can become disrupted, and excess calcium can be wasted in the urine (hypercalciuria) as the body tries to handle altered mineral balance and ongoing bone turnover. Together, aluminum toxicity and hypercalciuria capture the key contributors to PN-related bone disease in this setting. Other options aren’t as characteristic of PN-associated bone disease: vitamin D toxicity would raise calcium levels, not typical in this context; hypophosphatemia is a factor but pairing it with zinc deficiency doesn’t reflect the most critical PN-related bone risks; hypercalcemia and magnesium excess don’t align with the common PN-associated bone–mineral abnormalities seen in long-term PN.

The risk for PN-associated metabolic bone disease in patients on long-term parenteral nutrition centers on imbalances from the IV nutrition itself, especially exposure to aluminum and how calcium handling is managed. Aluminum toxicity from PN solutions is a well-recognized cause of impaired bone mineralization (osteomalacia) and contributes to overall bone disease in these patients. At the same time, calcium metabolism can become disrupted, and excess calcium can be wasted in the urine (hypercalciuria) as the body tries to handle altered mineral balance and ongoing bone turnover. Together, aluminum toxicity and hypercalciuria capture the key contributors to PN-related bone disease in this setting.

Other options aren’t as characteristic of PN-associated bone disease: vitamin D toxicity would raise calcium levels, not typical in this context; hypophosphatemia is a factor but pairing it with zinc deficiency doesn’t reflect the most critical PN-related bone risks; hypercalcemia and magnesium excess don’t align with the common PN-associated bone–mineral abnormalities seen in long-term PN.